Trial Profile
Intravitreal Alflibercept Injection (IAI) for Persistent Diabetic Macular Edema (DME) After Treatment With Bevacizumab And Ranibizumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 May 2019
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Bevacizumab; Ranibizumab
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms ROTATED
- 09 Apr 2019 Status changed from recruiting to completed.
- 17 Nov 2017 New trial record